Russell Petty

11PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsPatient safetyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial.

|Dec 19, 2025
Correction: Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.

Alan E Bilsland, Eilidh McCulloch, Sofie Degerman

|Nov 17, 2025
Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.

Alan E Bilsland, Eilidh McCulloch, Sofie Degerman

|Jul 10, 2025
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer.

Daniela Conticelli, Marco Volante, Filippo Pietrantonio

|Jul 04, 2025
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma.

Lindsay C Spender, Dale M Watt, Mark A Baxter

|Oct 29, 2023
Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.

Hollie A Clements, Tim J Underwood, Russell D Petty

Pageof 2

Frequent Collaborators

4 joint publications

Mark A Baxter

2 joint publications

Peter Hall

2 joint publications

Patricia Roxburgh

2 joint publications

Leslie Samuel